Surufatinib is a Small Molecule owned by Hutchison MediPharma, and is involved in 54 clinical trials, of which 17 were completed, 21 are ongoing, and 16 are planned.
Surufatinib is an anti cancer therapy. The drug candidate acts by inhibiting multiple kinases. It inhibits all three forms of vascular endothelial growth factor receptors (VEGFR-1,2,3). Epidermal growth factor attach to the receptor and activates the receptor. These pathways act in a coordinated manner to promote cell differentiation. The drug candidate also inhibits fibroblast growth factor receptor 1 (FGFR-1). Fibroblast growth factor (FGFs) binds to its receptor and activates it. Inhibition of the CSF-1R signaling pathway blocks the activation of tumor-associated macrophages, which are involved in suppressing immune responses against tumors.
The revenue for Surufatinib is expected to reach a total of $4.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Surufatinib NPV Report.
Surufatinib (Sulanda) is a potential antineoplastic and anti-angiogenic agent. It is formulated as capsules for oral route of administration. Sulanda is indicated for the treatment of non-pancreatic neuroendocrine tumors (“NETs”). Surufatinib is under development for the treatment of neuroendocrine tumors, solid tumors, primary peritoneal cancer, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, lymphoma, non-rhabdomyosarcoma soft tissue sarcoma, neuroendocrine tumors of pancreatic and non-pancreatic (Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)), thyroid and gallbladder cancer, non-small cell lung cancer, extrahepatic cholangiocarcinoma, medullary thyroid cancer, metastatic biliary tract carcinoma including extrahepatic cholangiocarcinoma (EHCC), endometrial cancer, colorectal cancer, neuroendocrine carcinoma, adenocarcinoma of the gastroesophageal junction, soft tissue sarcoma, small-cell lung cancer, gastric cancer, esophageal squamous cell carcinoma, intrahepatic cholangiocarcinoma (IHCC) or gallbladder biliary carcinoma (GBC), epithelial ovarian cancer and fallopian tube cancer. It is administered orally.
Hutchmed China Overview
Hutchmed China (Hutchmed) formerly known as Hutchison China MediTech is a biopharmaceutical company which discovers, develops, manufactures and commercializes drugs for the treatment of solid tumors and hematological malignancies; and immunological disorders. It also offers over-the-counter (OTC) pharmaceuticals and consumer healthcare products. Hutchmed also provides R&D services to other companies. It has a broad pipeline of drug candidates indicated for the treatment of immunological diseases, besides novel oral drug candidates for various cancers and inflammation. It operates in China, North America, Europe and Australia. The company offers prescription drugs to hospitals in China through direct sales force. It distributes consumer health products in China. Hutchmed is headquartered in Kowloon, Hong Kong.
The company reported revenues of (US Dollars) US$356.1 million for the fiscal year ended December 2021 (FY2021), an increase of 56.2% over FY2020. The operating loss of the company was US$207 million in FY2021, compared to an operating loss of US$196.7 million in FY2020. The net loss of the company was US$194.7 million in FY2021, compared to a net loss of US$125.7 million in FY2020.
Quick View – Surufatinib
|Highest Development Stage|